Candidemia
Antifungal medicine VFEND receives U.S. FDA approval for blood infection
Published in Gene Therapy Weekly, January 27th, 2005
Pfizer Inc announced that the U.S. Food and Drug Administration (FDA) approved the use of its extended-spectrum antifungal VFEND (voriconazole; IV for injection, tablets, and oral suspension) for the treatment of candidemia in nonneutropenic patients (those without low white blood cell counts) and the following Candida infections: disseminated (deep tissue) infections in skin and infections in abdomen, kidney, bladder wall, and wounds.
Bloodstream infections caused by Candida (candidemia) are the fourth most common type of hospital-acquired bloodstream infections in the Unites States and have the highest mortality rate.
According to the U.S. Centers...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2005-01-27)
More Articles from Gene Therapy Weekly
- Assisted Reproduction
Growth differentiation factor gene fragments treat porcine ovarian dysfunction - Cerebrovascular Disease
Homeobox D3 gene delivery initiates cerebral angiogenesis in mice - Gene Transfer
Jet injection and electroporation deliver plasmids to large muscles - Gene Transfer
Nucleotides targeting anti-apoptosis protein bind to erythroleukemia cells - Neurodegeneration
Beta-synuclein gene transfer protects mice from nervous system degeneration - Acute Myelogenous Leukemia
Clinical outcome not affected in pediatric AML patients with PTPN11 mutations - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
